273 related articles for article (PubMed ID: 27392760)
1. Systematic Review of Tumor Necrosis Factor Antagonists in Extraintestinal Manifestations in Inflammatory Bowel Disease.
Peyrin-Biroulet L; Van Assche G; Gómez-Ulloa D; García-Álvarez L; Lara N; Black CM; Kachroo S
Clin Gastroenterol Hepatol; 2017 Jan; 15(1):25-36.e27. PubMed ID: 27392760
[TBL] [Abstract][Full Text] [Related]
2. [The role of biologic therapy in the treatment of extraintestinal manifestations and complications of inflammatory bowel disease].
Kujundzić M
Acta Med Croatica; 2013 Apr; 67(2):195-201. PubMed ID: 24471303
[TBL] [Abstract][Full Text] [Related]
3. Skin Manifestations of Inflammatory Bowel Disease.
Greuter T; Navarini A; Vavricka SR
Clin Rev Allergy Immunol; 2017 Dec; 53(3):413-427. PubMed ID: 28643285
[TBL] [Abstract][Full Text] [Related]
4. Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease.
Barrie A; Regueiro M
Inflamm Bowel Dis; 2007 Nov; 13(11):1424-9. PubMed ID: 17567879
[TBL] [Abstract][Full Text] [Related]
5. Ustekinumab for Extra-intestinal Manifestations of Inflammatory Bowel Disease: A Systematic Literature Review.
Guillo L; D'Amico F; Danese S; Peyrin-Biroulet L
J Crohns Colitis; 2021 Jul; 15(7):1236-1243. PubMed ID: 33367674
[TBL] [Abstract][Full Text] [Related]
6. Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease.
Hanzel J; Ma C; Casteele NV; Khanna R; Jairath V; Feagan BG
Drugs; 2021 Feb; 81(3):333-347. PubMed ID: 33400241
[TBL] [Abstract][Full Text] [Related]
7. Vedolizumab Treatment in Extra-Intestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review.
Chateau T; Bonovas S; Le Berre C; Mathieu N; Danese S; Peyrin-Biroulet L
J Crohns Colitis; 2019 Dec; 13(12):1569-1577. PubMed ID: 31076751
[TBL] [Abstract][Full Text] [Related]
8. Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study.
Vavricka SR; Gubler M; Gantenbein C; Spoerri M; Froehlich F; Seibold F; Protic M; Michetti P; Straumann A; Fournier N; Juillerat P; Biedermann L; Zeitz J; Misselwitz B; Scharl M; Heinrich H; Manser CN; Safroneeva E; Raja Ali RA; Rogler G; Schoepfer AM; Greuter T;
Inflamm Bowel Dis; 2017 Jul; 23(7):1174-1181. PubMed ID: 28452862
[TBL] [Abstract][Full Text] [Related]
9. The role of anti-tumor necrosis factor-alpha therapy in Pyoderma gangrenosum associated with inflammatory bowel disease.
Reguiaï Z; Grange F
Am J Clin Dermatol; 2007; 8(2):67-77. PubMed ID: 17428111
[TBL] [Abstract][Full Text] [Related]
10. Review article: immunogenicity of anti-TNF biologics in IBD - the role of patient, product and prescriber factors.
Moss AC; Brinks V; Carpenter JF
Aliment Pharmacol Ther; 2013 Nov; 38(10):1188-97. PubMed ID: 24118102
[TBL] [Abstract][Full Text] [Related]
11. Biologics for extraintestinal manifestations of IBD.
Vavricka SR; Scharl M; Gubler M; Rogler G
Curr Drug Targets; 2014; 15(11):1064-73. PubMed ID: 25198785
[TBL] [Abstract][Full Text] [Related]
12. Effects of Combination Therapy With Immunomodulators on Trough Levels and Antibodies Against Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease: A Meta-analysis.
Qiu Y; Mao R; Chen BL; Zhang SH; Guo J; He Y; Zeng ZR; Ben-Horin S; Chen MH
Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1359-1372.e6. PubMed ID: 28232073
[TBL] [Abstract][Full Text] [Related]
13. Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease.
Fleisher M; Marsal J; Lee SD; Frado LE; Parian A; Korelitz BI; Feagan BG
Dig Dis Sci; 2018 Apr; 63(4):825-833. PubMed ID: 29484571
[TBL] [Abstract][Full Text] [Related]
14. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series.
Afzali A; Wheat CL; Hu JK; Olerud JE; Lee SD
J Crohns Colitis; 2014 Jun; 8(6):480-8. PubMed ID: 24268978
[TBL] [Abstract][Full Text] [Related]
15. How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?
Ward MG; Irving PM; Sparrow MP
World J Gastroenterol; 2015 Oct; 21(40):11331-42. PubMed ID: 26525434
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy.
Passarini B; Infusino SD; Barbieri E; Varotti E; Gionchetti P; Rizzello F; Morselli C; Tambasco R; Campieri M
Dermatology; 2007; 215(4):295-300. PubMed ID: 17911986
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of infliximab for extraintestinal manifestations of inflammatory bowel disease.
Siemanowski B; Regueiro M
Curr Treat Options Gastroenterol; 2007 Jun; 10(3):178-84. PubMed ID: 17547856
[TBL] [Abstract][Full Text] [Related]
18. Biological Therapy in Pediatric Inflammatory Bowel Disease: A Systematic Review.
Corica D; Romano C
J Clin Gastroenterol; 2017 Feb; 51(2):100-110. PubMed ID: 27636407
[TBL] [Abstract][Full Text] [Related]
19. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
[TBL] [Abstract][Full Text] [Related]
20. The impact of vedolizumab therapy on extraintestinal manifestations in patients with inflammatory bowel disease: A systematic review and meta-analysis.
Zheng DY; Wang YN; Huang YH; Jiang M; Ma YN; Dai C
J Gastroenterol Hepatol; 2024 May; ():. PubMed ID: 38740543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
